Skip to main content

Table 3 OS and OS rate in high-risk and low-risk groups according to our model risk score in the training and validation cohort

From: A multi-parametric prognostic model based on clinical features and serological markers predicts overall survival in non-small cell lung cancer patients with chronic hepatitis B viral infection

Parameter

Training cohort

Validation cohort

High-risk group

Low-risk group

Total

High-risk group

Low-risk group

Total

No. of patients

86

59

145

28

28

56

OS

 Median

15.0

63.0

 

12.5

59.0

 

 IQR

7.0–40.0

38.0–74.0

 

7.25–21.50

33.50–72.25

 

No. of OS

 At 1 year

51 (59.3%)

58 (98.1%)

109 (69.7%)

16 (57.1%)

25 (89.3%)

41 (73.2%)

 At 3 year

23 (26.7%)

45 (76.3%)

68 (46.9%)

4 (14.3%)

20 (71.4%)

24 (42.9%)

 At 5 year

10 (11.6%)

36 (61.0%)

46 (31.7%)

1 (3.6%)

14 (50.0%)

15 (26.8%)

  1. OS overall survival, IQR interquartile range